Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc’s (NASDAQ:AGLE) marketing application seeking approval for pegzilarginase for the treatment of…
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…
FDA Accepts Krystal Biotech’s Filing For Genetic Skin Disorder Candidate Under Priority Review
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB).
Caribou’s Blood Cancer Candidate Shows Response Rates Better Than Novartis,’ This Analyst Writes
Last week, Caribou Biosciences Inc (NASDAQ:CRBU) announced Q2 earnings and provided updated results from the Phase 1 ANTLER trial of the company’s…
Blueprint Medicines’ Ayvakit ‘Will Garner Approval’ Despite Questions, This Analyst Says
HC Wainwright has cut the price target on Blueprint Medicines Corporation (NASDAQ:BPMC) from $100 to $80 and reiterated the Buy rating. The analyst…
Analysts Are Bullish On 89bio’s NASH Data Slated For Early Next Year
Earlier today, 89bio Inc (NASDAQ:ETNB) concluded enrollment in ENLIVEN Phase 2b trial of pegozafermin for non-alcoholic steatohepatitis (NASH), enabling topline results in…
Biden Officials Seek To Boost Supply For Monkeypox Vaccines, Treatment
Top Biden administration officials are poised to lay out new steps to accelerate the U.S. response amid the spread of monkeypox and demand for vaccines & treatments.
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
Exscientia Plc (NASDAQ:EXAI) has ended its collaboration with Bayer AG (OTC: BAYRY) following the achievement of a drug discovery milestone. Exscientia will retain the…
Cassava Insiders Got A Lot Richer As Shares Rebound Following Refutation of Data Manipulation Claims
Journal of Prevention of Alzheimer’s Disease (JPAD) informed Cassava Sciences Inc (NASDAQ:SAVA) about no convincing evidence to support data manipulation allegations…
Novavax’s Covid-19 Vaccine Cleared For Use In New Zealanders Aged 12-17
New Zealand’s Medsafe has granted expanded provisional approval for Novavax Inc’s (NASDAQ:NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in adolescents aged 12 through 17.…